Presentations of the ESMO Magnitude of Clinical Benefit Scale
Since its publication in Annals fo Oncology, the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) has been presented on a number of occassions
During an ESMO Asia 2015 Special Session, Resource constraints as a barrier to lung cancer management: Developing nations, C. Zielinski presented the ESMO Magnitude of Clinical Benefit Scale.
The scale was presented at the ESMO Society Session (28 September) during the European Cancer Congress 2015 in Vienna, Austria. E.G. de Vries, Netherlands, presented the scale and A. Eniu, Romania explained how the scale is applied using the data from the ESMO Anti-Neoplastic Medicines Surveys.
In addition, aspects of the ESMO-MCBS were highlighted and discussed during three further sessions at ECC 2015:
- ESO Society Session: ‘Is innovation Affordable?’, 26 September: The ESMO initiative on affordable drugs, Speaker: M. Piccart (Belgium)
- Oncopolicy Forum: Inequalities in Treatment Outcomes, 27 September: The Value of anticancer treatment, Speaker: E. G. de Vries (Netherlands)
- Special Session: Evaluating Clinical Benefit of Cancer Drugs Across Tumours, 28 September: Chair: E.G. de Vries (Netherlands); Clinical Benefit scale: The European proposal, Speaker: M. Piccart (Belgium); Clinical Benefit scale: The challenge of fairness, Speaker: U. Dafni (Greece)
ESMO-MCBS presented at the ESMO/ASCO Joint Session (30 May) during ASCO 2015, Chicago
World Cancer Congress 2016, Paris, France (31 October – 3 November 2016). The ESMO Magnitude of clinical benefit scale and the value of cancer care, E. G. de Vries (Netherlands)